KROS earnings: real EPS beat/miss history, analyst consensus Buy, P/E -4.18. Updated 2026-07-23.
Keros Therapeutics (KROS) Research Hub
Keros Therapeutics (KROS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.08 USD (-2.03%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.18, market cap 0.33B. This hub links to the full technical, earnings and options research available for KROS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.08 USD (-2.03%) |
| 52-week range | 9.69 USD – 12.04 USD |
| Trend regime | Range |
| 14-day RSI | 49 (Neutral) |
| Trailing P/E | -4.18 |
| Market cap | 0.33B |
| Dividend yield | 0.00% |
Available research for KROS
Covered Call on KROS: how it works, illustrative setup around the real 11.08 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KROS: how it works, illustrative setup around the real 11.08 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KROS: how it works, illustrative setup around the real 11.08 USD price, max profit/loss, breakeven and when to use it. Educational.
KROS technical analysis: range, last 11.08 USD, RSI 49, 52w range 9.69 USD–12.04 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KROS in?
Keros Therapeutics (KROS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KROS in an uptrend or downtrend?
As of 2026-09-11, KROS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KROS's trailing P/E ratio?
KROS's trailing P/E is -4.18, with a market cap of 0.33B. See the earnings research page for full valuation detail.